Enantioseparation of solriamfetol and its major impurity phenylalaninol by capillary electrophoresis using sulfated gamma cyclodextrin [PDF]
, 2021 R-solriamfetol is a recently approved drug used for the treatment of excessive sleepiness associated with narcolepsy and sleep apnea. Herein, a capillary electrophoretic method was developed, enabling the simultaneous analysis of the API and its S ...
Bianka Várnai +14 more
core +1 more source
Obstructive Sleep Apnoea Treatments-Where Are We Now? [PDF]
RespirologyRespirology, Volume 30, Issue 10, Page 920-922, October 2025.
Luu S, Lee D, Yee BJ.
europepmc +2 more sources
Sleep, 2021 Abstract Introduction Solriamfetol (Sunosi®), a dopamine/norepinephrine reuptake inhibitor, is approved (US and EU) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75–150 mg/day) or obstructive sleep apnea (OSA) (37.5–150 mg/day).
Michael Thorpy +6 more
openaire +1 more source
The orexin story and orexin receptor antagonists for the treatment of insomnia
Journal of Sleep Research, Volume 32, Issue 6, December 2023., 2023 Summary Insomnia is present in up to one third of the adult population worldwide, and it can present independently or with other medical conditions such as mental, metabolic, or cardiovascular diseases, which highlights the importance of treating this multifaceted disorder.
Clemens Muehlan +3 more
wiley +1 more source
Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression [PDF]
, 2022 Given the high rate of depression associated with narcolepsy or obstructive sleep apnea (OSA), this analysis compared effects of solriamfetol treatment of excessive daytime sleepiness (EDS) in participants with/without a history of depression (DHx+/DHx-).
Babson, Kimberly +8 more
core +1 more source
Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database [PDF]
HeliyonHe B, Zheng W.
exaly +2 more sources
Activated Wake Systems in Narcolepsy Type 1
Annals of Neurology, Volume 94, Issue 4, Page 762-771, October 2023., 2023 Objective Narcolepsy type 1 (NT1) is assumed to be caused solely by a lack of hypocretin (orexin) neurotransmission. Recently, however, we found an 88% reduction in corticotropin‐releasing hormone (CRH)‐positive neurons in the paraventricular nucleus (PVN).
Ling Shan +11 more
wiley +1 more source
Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy
Clinical Therapeutics, 2022 Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved (in the United States and European Union) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75-150 mg/d) or obstructive sleep apnea (OSA) (37.5-150 mg/d). This study characterized real-world titration strategies for patients with narcolepsy (with or without ...
Michael J, Thorpy +7 more
openaire +2 more sources
Internal Medicine Journal, Volume 53, Issue 10, Page 1783-1789, October 2023., 2023 Abstract Background Hypersomnias of central origin (HOCO) are diverse in origin and symptomatology and remain poorly described in an Australian population. We hypothesised that the rate of human leukocyte antigen (HLA) DQB1*0602 positivity in the Australian cohort would be comparable to international registries.
Lachlan Stranks +6 more
wiley +1 more source
Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. [PDF]
, 2021 STUDY OBJECTIVES: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the United States and European Union for excessive daytime sleepiness in adults with narcolepsy (75-150 mg/day) or obstructive sleep apnea (OSA; 37.5-150 mg/day).
Mayer, G. +33 more
core +1 more source